GAO Says Federal Research Needed on Safety of Portable Cellular Telephones

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

PARIS, France--Dr. Bernard Fisher, Distinguished Service Professor of Surgery, University of Pittsburgh, was presented with the Third Claude Jacquillat Award for Achievement in Clinical Oncology at the Fifth International Congress of Anti-Cancer Chemotherapy.

PARIS, France--Dr. Bernard Fisher, Distinguished Service Professorof Surgery, University of Pittsburgh, was presented with the ThirdClaude Jacquillat Award for Achievement in Clinical Oncology atthe Fifth International Congress of Anti-Cancer Chemotherapy.

Established in 1991 in memory of Claude Jacquillat, a leader inclinical cancer research, this award honors those who have madeoutstanding contributions in the treatment of cancer patients.

'Man of Courage'

The award statement called Dr. Fisher's contributions inspiringand quoted Dr. George Canellos, past president of the AmericanSociety of Clinical Oncol-ogy: "Dr. Fisher will stand tallas a man of courage who, throughout his career, used science tochallenge tradition, as well as a man of dedication who improvedthe lives of women with breast cancer."

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content